XBiotech Inc. Earnings Per Share Disclosure
8. Net Loss Per Share
The following summarizes the computation of basic and diluted net income(loss) per share for the years ended December 31, 2024, and 2023 (in thousands, except share and per share data):
|
Year Ended December 31, |
||||||||
|
2024 |
2023 |
|||||||
|
Net loss |
$ | (38,531 | ) | $ | (24,557 | ) | ||
|
Weighted-average number of common shares—basic |
30,460,980 | 30,438,459 | ||||||
|
Net loss per share—basic |
$ | (1.26 | ) | $ | (0.81 | ) | ||
|
Weighted-average number of common shares—diluted |
30,460,980 | 30,438,459 | ||||||
|
Net loss per share—diluted |
$ | (1.26 | ) | $ | (0.81 | ) | ||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Mar 18, 2025 | Showing above |
| 2023 | Mar 15, 2024 | |
| 2018 | Mar 14, 2019 | |
| 2017 | Mar 16, 2018 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.